Back to discover
Drug

Catequentinib

Approved medicine
ClassVascular endothelial growth factor receptor 3 inhibitorResearchOngoing clinical research

Also known as 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine, Anlotinib, Anrotenib, Arotinib.

RxNorm1939861ChEMBLCHEMBL4303201UNIIGKF8S4C432
51
Active clinical trials
4
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant Advanced Non-small Cell Lung Cancer Patients: a Multi-center, Open-label, Phase 1/2 Study

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans

Clinical trial2026-06-16Results expected Q4 2028 · ClinicalTrials.gov

Anlotinib Plus Chemotherapy as Neoadjuvant Treatment of High-risk, Early-stage Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer: A Prospective, Single-arm, Single-center, Phase II Clinical Study

Clinical trial2026-06-10Results posted · ClinicalTrials.gov

A Multicenter, Open-label, Randomized Controlled Phase II/III Study Evaluating the Efficacy and Safety of QL1706 in Combination With Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer

Clinical trial2026-06-09Results expected Q4 2028 · ClinicalTrials.gov

A Single-arm, Phase II Interventional Study to Evaluate the Efficacy and Safety of Lomustine Combined With Anlotinib in Patients With Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Further Lines of Treatment

Clinical trial2026-06-08Results expected Q2 2028 · ClinicalTrials.gov

A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Anlotinib Capsules for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)/Progressive Fibrosis-interstitial Lung Disease (PF-ILDs)

Clinical trial2026-06-05Results expected Q3 2026 · ClinicalTrials.gov

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

Efficacy and Safety of Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure: A Single-arm, Open-label, Multicenter Phase II Clinical Study

Clinical trial2026-05-31Primary completion · ClinicalTrials.gov

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Clinical trial2026-05-31Primary completion · ClinicalTrials.gov

A Prospective Multicenter Randomized Controlled Study of Preoperative Radiotherapy Combined With Targeted Therapy With or Without Immunotherapy for Soft Tissue Sarcoma

Clinical trial2026-05-28Results expected Q4 2031 · ClinicalTrials.gov

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)

Clinical trial2026-05-28Results expected Q4 2027 · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Catequentinib
Aliases & brands
1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amineAnlotinibAnrotenibArotinib
RxNorm CUI
1939861
ChEMBL ID
CHEMBL4303201
UNII
GKF8S4C432
Primary mechanism
Vascular endothelial growth factor receptor 3 inhibitor

Pharmacology & targets

4 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Vascular endothelial growth factor receptor 3
FLT4 · P35916
INHIBITORVascular endothelial growth factor receptor 3 inhibitor
Vascular endothelial growth factor receptor 2
KDR · P35968
INHIBITORVascular endothelial growth factor receptor 2 inhibitor
Mast/stem cell growth factor receptor Kit
KIT · P10721
INHIBITORStem cell growth factor receptor inhibitor
Platelet-derived growth factor receptor beta
PDGFRB · P09619
INHIBITORPlatelet-derived growth factor receptor beta inhibitor

Clinical trials

167 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
167
registered trials across all phases
LATEST COMPLETION 2026
51
Active studies
48
Recruiting
40
Late-stage (III+)
23
Completed
93
Discontinued
PHASE DISTRIBUTIONn = 167
Phase 110Phase 1 / 214Phase 2103Phase 2 / 311Phase 311Phase 47Phase N / A11

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Multicenter Prospective-Retrospective Real-World Study Evaluating Conversion-to-Surgery and Survival After Genotype-Matched Neoadjuvant Systemic Therapy in Locally Advanced Thyroid Carcinoma

Not yet recruitingPH IVFujian Medical Universityn=3352028

A Prospective, Open-Label, Single-Arm Clinical Study of Anlotinib Combined With Doxorubicin Monotherapy and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

RecruitingPH IVGuangdong Provincial People's Hospitaln=392028

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Not yet recruitingPH IVThe First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicinen=332028

A Real-world Study of Benmelstobart, Anlotinib and Chemotherapy Regimen as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Not yet recruitingPH IVPeking Union Medical College Hospitaln=502027

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Not yet recruitingPH IVChina Medical University, Chinan=312027

Recent completions

Trials that read out recently, adding to the completed evidence base.

An Open-label Phase II Trial Evaluating the Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in Early-stage Triple-negative Breast Cancer（NeoSACT）

CompletedPH IIGuangdong Provincial People's Hospitaln=292026

A Phase Ib Study on Toripalimab Combined With Anlotinib and SBRT for Patients With Untreated Brain Metastases of Driven Gene-negative Non-small Cell Lung Cancer

CompletedPH IHubei Cancer Hospitaln=132025

Safety and Efficacy of Osimertinib Combined With Anlotinib in EGFRm+, Treatment-naïve IIIb/IV NSCLC Patients: a Prospective, Single Arm, Phase Ib/IIa Study

CompletedPH I/IIShanghai Chest Hospitaln=252024

A Open-label, Multicenter Phase II Study of TQB2450 Injection or Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

CompletedPH IIChia Tai Tianqing Pharmaceutical Group Co., Ltd.n=1702024

A Multicenter Study of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as First-line Therapy in Patients (Pts) With Metastatic Pancreatic Cancer: PAAG.

CompletedPH IIThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical Schooln=662024

Combined MEK Inhibitor Trametinib and RTK Inhibitor Anlotinib Therapy in Non-G12C KRAS-Mutant Non-Small Cell Lung Cancer Patients

CompletedPH IShanghai Chest Hospitaln=332024
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials